CRBP biotech catalysts & pipeline

CORBUS PHARMACEUTICALS HOLDINGS INC · Data as of 2026-10-25

Upcoming catalysts

CRB-701 — Regulatory decision

H2 2026

Registrational pathway update following FDA engagement

Source filing

CRB-701 — Topline data

Q1 2027

Topline ORR data expected in Q1 2027

Source filing

CRB-701 — Interim data

Q1 2028

Report registrational interim 2L ORR data — Q1 2028

Source filing

CRB-701 — NDA/BLA submission

2H 2028

Commence registrational study in 2L OPSCC CRB-701 + pembrolizumab in 1L OPSCC data Interim ORR readout in 2L OPSCC Potential BLA filing for 2L OPSCC Sept 2026 Q1 2027 1H 2028 2H 2028 CRB-701

Source filing

CRB-913 — Conference presentation

Late 2026

Present Phase 1b dataset at ObesityWeek as a late breaker

Source filing

CRB-913 — Conference presentation

Nov 14–Nov 17

The data from the CANYON-1 Phase 1b trial will be detailed in a late-breaking presentation at ObesityWeek® 2026, to be held November 14 – 17, 2026.

Source filing

Explore the free biotech catalyst calendar